Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis
Abstract Hereditary transthyretin (TTR) amyloidosis (ATTRv) is an autosomal dominant, systemic disease transmitted by amyloidogenic mutations in the TTR gene. To prevent the otherwise fatal disease course, TTR stabilizers and mRNA silencing antisense drugs are currently approved treatment options. W...
Saved in:
Main Authors: | Maike F. Dohrn, Jessica Medina, Karmele R. Olaciregui Dague, Ernst Hund |
---|---|
Format: | article |
Language: | EN |
Published: |
BMC
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/9fb44f289ffd423bb7e7aa14a4bebefc |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Oligonucleotides
Published: (2003) -
Epidemiology of variant transthyretin amyloidosis at a reference center in Argentina
by: Maria S. Saez, et al.
Published: (2021) -
Retinitis pigmentosa associated with systemic light chain amyloidosis (AL amyloidosis)
by: Salem Bouomrani, et al.
Published: (2021) -
Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies
by: Craig S. McIntosh, et al.
Published: (2021) -
Subcutaneous scalp nodule as the presenting symptom of systemic light-chain amyloidosis
by: Joseph Tadros, et al.
Published: (2018)